Review article · 2020 · Open access
Clinical trials of new drugs for Alzheimer disease
Journal of Biomedical Science, 27(1), 18 · Published 6 January 2020 · DOI 10.1186/s12929-019-0609-7
In brief
“Clinical trials of new drugs for Alzheimer disease” is a 2020 review article by Li‐Kai Huang and 2 co-authors, published in Journal of Biomedical Science. OpenAlex counts 718 citations as of 15 November 2026, which puts it in the top 1% of works published in 2020 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of Biomedical Science.
- Citations
- 718
- Most cited in
- 2021 (150)
- Field-weighted impact
- 14.40
- References
- 83
- Authors
- 3
Abstract
Alzheimer disease (AD) accounts for 60-70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies.In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at clinicaltrials.gov. We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Huang, L., Chao, S.-P., & Hu, C. (2020). Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 27(1), 18. https://doi.org/10.1186/s12929-019-0609-7
MLA 9
Huang, Li‐Kai, et al. “Clinical trials of new drugs for Alzheimer disease.” Journal of Biomedical Science, vol. 27, no. 1, 2020, p. 18. https://doi.org/10.1186/s12929-019-0609-7.
Chicago
Huang, Li‐Kai, Shu-Ping Chao, and Chaur‐Jong Hu. 2020. “Clinical trials of new drugs for Alzheimer disease.” Journal of Biomedical Science 27 (1): 18. https://doi.org/10.1186/s12929-019-0609-7.
Harvard
Huang, L., Chao, S.-P. and Hu, C. (2020) ‘Clinical trials of new drugs for Alzheimer disease’, Journal of Biomedical Science, 27(1), p. 18. doi:10.1186/s12929-019-0609-7.
IEEE
L. Huang, S.-P. Chao, and C. Hu, “Clinical trials of new drugs for Alzheimer disease,” Journal of Biomedical Science, vol. 27, no. 1, p. 18, 2020, doi: 10.1186/s12929-019-0609-7.
BibTeX
@article{huang2020clinical,
title = {{Clinical trials of new drugs for Alzheimer disease}},
author = {Huang, Li‐Kai and Chao, Shu-Ping and Hu, Chaur‐Jong},
journal = {Journal of Biomedical Science},
year = {2020},
volume = {27},
number = {1},
pages = {18},
doi = {10.1186/s12929-019-0609-7},
url = {https://doi.org/10.1186/s12929-019-0609-7}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2020 | 68 | |
| 2021 | 150 | |
| 2022 | 136 | |
| 2023 | 147 | |
| 2024 | 105 | |
| 2025 | 71 | |
| 2026 | 41 |
Its field-weighted citation impact is 14.40: it has been cited 14.40 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- clinical trials
- amyloid hypothesis
- amyloid-beta
- anti-amyloid therapy
- anti-tau therapy
- cholinesterase inhibitors
- NMDA receptor antagonists
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Huang, L., Chao, S.-P., & Hu, C. (2020). Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 27(1), 18. https://doi.org/10.1186/s12929-019-0609-7
How many times has this paper been cited?
718 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Journal of Biomedical Science.
Who wrote this paper?
Li‐Kai Huang, Shu-Ping Chao, Chaur‐Jong Hu.
What is the DOI of this paper?
10.1186/s12929-019-0609-7. The permanent link is https://doi.org/10.1186/s12929-019-0609-7.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.